We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Interleukin 1 Receptor and Alzheimer's Disease-Related Neuroinflammation

Huanhuan Wang and Xizhen Wang

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.69067>

Abstract

Neuroinflammation as one of the pathogenic mechanisms concerning to the development of Alzheimer's disease (AD) has aroused more attention since last decades. Amyloid beta (A β) peptide generation is supposed to be the initial event in AD progress, followed by neuronal impairment, neuroinflammation, and severe substantial neuronal dysfunction. Interleukin-1 receptor (IL-1R) as one of the most prevalent inflammatory mediated surface receptors, participates not only in peripheral inflammation but also in AD-related neuroinflammation. In microglia, IL-1R activation triggers the downstream signaling and the production of proinflammatory cytokines and chemokines. IL-1R signaling also participates in AD-related A β -induced inflammasome activation. Besides, IL-1R activation in neurons may increase APP non-amyloid pathway by modulation of APP α -secretase activity, which may prevent neurotoxic A β generation. Thus, the exact role of IL-1R signaling in AD development and neuronal functions is somehow tricky.

Keywords: interleukin 1 receptor, Alzheimer's disease, neuroinflammation

1. Introduction

Alzheimer's disease (AD) is kind of neurodegenerative disease, which affects elder's health and living quality. There are some hypotheses raised up for the pathogenesis of the disease, such as amyloid cascade and tau hyperphosphorylation. Besides, neuroinflammation induced by neurotoxic amyloid β (A β) peptide is also considered contribute to the development of AD. Interleukin-1 receptor (IL-1R) is one of the inflammation-related surface receptors that are distributed widely in various tissues and cells in the body. Evidence has been shown that IL-1R-mediated neuroinflammation may be closely related to pathogenesis and

development of AD. In the current chapter, AD-related neuroinflammation and the participation of IL-1R in such progress would be reviewed and discussed in detail.

2. Alzheimer's disease

As a kind of chronic neurodegenerative disease, AD usually starts slowly and gets worse over comparatively longer time. The initial symptoms of AD are often mistaken with normal aging. The most common early symptom for AD is the difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms may include problems with language, disorientation (easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioral issues. AD patients may suffer from the disease symptoms for years and especially at the later stage of the progress.

AD is currently supposed to be the cause of approximately 60–70% of total dementia cases. There is a large amount of data about potential risk factors for AD, including age [1], genetics [2], and injury [3]. Many treatable medical conditions are also associated with an increased risk of AD, including stroke [4], diabetes [5], midlife hypertension [6], and hypercholesterolemia [7, 8].

The early identification of molecular pathological description of AD was the functional reduction of cholinergic nerve system in the cerebral cortex, like the remarkable reduction in choline acetyltransferase (ChAT) [9]. Later, senile plaques and neurofibrillary tangles (NFTs), two typical protein depositions, were confirmed related to AD [10]. The main component of senile plaques is A β peptide; while NFTs are made from abnormal tau proteins [11]. A 42-amino acid long form of A β (A β 42) was found as the main content in fibrillar A β peptides [12]. A β 40, which is also found in the plaque, although is normally more abundantly produced by cells, contributes to the lower portion of the plaque [13]. Compared to A β 40, A β 42 is the more hydrophobic form that aggregates more easily and quickly [14]. NFTs are formed by hyperphosphorylated tau protein. As the raise of A β concentration, tau protein happens to be more easily phosphorylated, leading to an imbalance of various kinases and phosphatases [15]. Consequently, mass transport and impaired impulse occurs in neurons, followed by severe neuronal dysfunction.

Thus, the amyloid hypothesis puts A β accumulation at the core of AD pathogenesis. A β is the sequential proteolytic product of its precursor amyloid precursor protein (APP). APP is a type I transmembrane protein, consisted of a large N-terminal ectodomain, a transmembrane domain, and a short cytoplasmic domain. The A β peptide generation is supposed to be influenced by the pattern of cleavage from APP by α , β , and γ -secretases [16]. APP can be processed in two different pathways, the amyloid, and non-amyloid pathway. In the amyloid pathway, APP can be cleaved by β -secretase (BACE1), releasing the soluble APP β fragment (sAPP β); and the C-terminal fragment (CTF) is still in the membrane and can be cleaved by γ -secretase (presenilin1, PS1) to release A β [17]. This process leads to A β generation, aggregation, and deposit. In the other non-amyloid pathway, APP can be cleaved by α -secretase (ADAM10/17), releasing soluble APP α fragment (sAPP α). The cleavage site of α -secretase is

between the sites of β - and γ -secretase. So the non-amyloid pathway can reduce the damage induced by $A\beta$ on neurons.

Consider to the crucial role of $A\beta$ in the amyloid cascade, therapeutic approaches related to APP metabolic pathways were always under careful and detail research and develop [18]. Those therapeutic approaches include inhibition of $A\beta$ monomers developing into toxic oligomers or enhancement of clearance and disaggregation of fibrillar aggregates from cerebral cortex [19]; modulation of the fate and toxicity of $A\beta$ using antibodies against $A\beta$ [20]. However, the only clinical effective therapeutic approach so far is the treatment and enhancement of the functions of cholinergic neurons. Acetylcholinesterase (AChE) inhibitors, galantamine, and rivastigmine were thought to improve cognition and indirectly help function and behavior in patients with AD [21–23]. Such treatments for AD have been widely available since the mid-1990s, but these drugs do not treat the underlying mechanism, so the effects are limited.

3. AD-related neuroinflammation

As described above, the amyloid hypothesis was raised up as the most popular and acceptable pathogenesis mechanism for AD. The initial changes of the cascade happen to $A\beta$ metabolism. The $A\beta$ balance in favor of $A\beta_{42}$ followed by the formation of diffuse plaques can induce the toxic effect to neurons to different extends. The diffuse $A\beta$ plaques can then convert to more toxic $A\beta$ deposit fibrillars. $A\beta$ triggers the activation of the cellular signaling cascade, the induction of inflammatory enzyme systems in a vicious cycle and finally the expression and secretion of proinflammatory cytokines. The activation of microglial and astrocyte, together with the corresponding inflammatory reactions, is another important event in AD pathogenesis. Both aggregated amyloid fibrils and inflammatory mediators secreted by microglia contribute to neuronal dystrophy. NFTs occur under such condition, which enhances neuronal dysfunction and death. The widespread neuronal dysfunction is regarded as the immediate cause of the disease [18, 24]. On the basis of these observations, $A\beta$ has become a major pharmacological target for the treatment of the disease. However, such trails of treatment have not reached a satisfactory outcome. Thus, the AD-related neuroinflammation starts to sneak into current research attention.

In parallel, neuroinflammation has been implicated in contributing to the etiology of AD. Epidemiological and prospective population-based studies show an association between suppression of inflammation and reduced risk for AD [25, 26]. The protective effects of non-steroidal anti-inflammatory drugs (NSAIDs) against AD development [27] further support the neuroinflammation hypothesis. In animals, the beneficial effects of NSAIDs have also been confirmed, including behavioral improvement and reductions in glial activation, $A\beta$ levels, and plaque size [28]. Inflammatory responses to amyloidosis have also been observed in animal models overexpressing $A\beta$ [29, 30]. Proinflammatory cytokines, such as (interleukin-1) IL-1, IL-6, and tumor necrosis factor α (TNF α), are elevated in the plasma, brains, and cerebrospinal fluid of patients with AD or mild cognitive impairment, whereas anti-inflammatory

cytokines are decreased [31, 32]. Besides, inhibition of $\text{TNF}\alpha$ signaling has been shown to attenuate AD-like pathology and cognitive impairments in transgenic mouse models, as well as in AD patients [33, 34].

Inflammation is a complex cellular and molecular response to insults (stress, injury or infection), an attempt to defend against these insults. AD-associated inflammation is generally considered as a secondary response to the pathological lesions evoked by $\text{A}\beta$ [35, 36]. AD-related inflammatory response is supposed to be driven mainly by activated microglia [37, 38].

The activation of microglia has been reported in both AD patients and animal models [39], accompanied by increased levels of specific chemokines and cytokines [40]. Microglia surrounding plaques stain positive for activation markers and proinflammatory mediators, including cyclooxygenase-2 (Cox-2), monocyte chemoattractant protein 1 (MCP-1), $\text{TNF}\alpha$, transforming growth factor- β (TGF β), IL-1 α , IL-1 β , and IL-6 [41–43]. $\text{A}\beta$ and its fibrils can induce self-defense, inflammatory responses via pattern recognition receptors (PRRs), such as toll-like receptors (TLRs) [44, 45]. $\text{A}\beta$ aggregates interact with microglial receptors like TLR4, CD14, CD36, CD47, the receptor for advanced glycation end products (RAGE), and some integrins [46–50]. More recently, it has been reported that $\text{A}\beta$ activates microglia through its interaction with the APP present in the membrane of these cells [51], which defines a novel function of APP in microglial regulation of the inflammatory response in AD.

Microglial activation seems to be the comparative early event in AD pathological development. Imaging study results showed that reactive microglia can be detected at the very early clinical stage of the disease [39]. In AD mouse model, microglial activation was observed before amyloid plaque formation [52]. Once activated, microglia can produce several proinflammatory signal molecules, including cytokines, growth factors, chemokines, and cell adhesion molecules. Besides, Microglia may also play a role in plaque evolution by phagocytosing and/or degrade deposited $\text{A}\beta$. Many different laboratories have shown that microglia, both *in vivo* and in culture, phagocytose exogenous fibrillar $\text{A}\beta$ [53, 54].

4. Interleukin 1 receptor

IL-1R family belongs to one category of TIR domain-containing receptor superfamily. The TIR domain-containing receptors are a large family of molecules involved in the activation of innate immunity [55]. The TIR superfamily can be broadly divided into two main groups: the immunoglobulin (Ig) domain-bearing receptors and the receptors with a leucine-rich repeat (LRR) domain [56, 57]. The Ig domain subgroup of TIR receptors includes 10 members of the IL-1R family, whereas the LRR group includes the toll-like receptors (TLR). When an agonist IL-1 family cytokine binds to its specific TIR-containing receptor, the initiation of IL-1R activation signaling occurs [56]. The signaling pathway involves the recruitment of adapter molecule MyD88 and kinase IRAK, followed by interaction with TRAF6. The final step is the phosphorylation of the inhibitory molecule I κ B by I κ B kinase complex leading to relocalization of transcription factor NF- κ B. NF- κ B is translocated into the nucleus and intermediates inflammatory immune response [58]. NF- κ B is a major inflammatory switch that comprises a

family of transcription factors that regulate expression of various proinflammatory cytokines (IL-1, IL-6, IL-8 and TNF α), chemokines, antiapoptotic factors and stress factors [59].

IL-1 family is the typical ligands for IL-1R and its activation. IL-1 family includes a set of cytokines, some of which have been demonstrated to play a critical role in host responses to pathogens and other noxious agents [60]. IL-1 α and IL-1 β are two most prevalent ligands that are supposed to trigger the activation of IL-1R. IL-1 α/β are endogenous pyrogens with activities similar to lipopolysaccharides (LPS), which are the major molecular components of the outer membrane of Gram-negative bacteria [61].

One of IL-1R ligand cytokine IL-1 β appears to play an important role in AD. IL-1 β level was confirmed obviously in and around the area of A β deposit [62, 63]. The inhibition of IL-1 signaling by IL-1R knockout could significantly relief the A β burden in transgenic AD mice [64]. And the protective impact by IL-1R knockout was believed to be dependent on attenuated AD-related neuroinflammation [65]. Besides, the inflammation- or IL-1 β -induced pathological tau development has also been well documented [66–68]. The inhibition of IL-1 signaling significantly suppressed the activation of cdk5/p25, GSK-3 β , and p38-MAPK, all major kinases that phosphorylate tau in neurons. Another study demonstrated a direct effect of IL-1 β secreted by microglia on neurons and subsequent activation of p38-MAPK and accumulation of tau phosphorylation [69]. NSAIDs could be repurposed as NLRP3 inflammasome inhibitors that provide neuroprotective impact against AD [70].

5. IL-1R signaling and inflammasome

Inflammasomes are responsible for the maturation of pro-inflammatory cytokines such as interleukin IL-1, IL-18, and IL-33 and activation of inflammatory cell death, pyroptosis [71]. The inflammasome is a multiprotein oligomer consisting of caspase 1, PYCARD, NALP, and sometimes caspase 5 (also known as caspase 11 or ICH-3). It is expressed in myeloid cells and is a component of the innate immune system. Analogous to the apoptosome, which activates apoptotic cascades, the inflammasome activates an inflammatory cascade. Once active, the inflammasome binds to pro-caspase-1 (the precursor molecule of caspase-1), either homotypically via its own caspase activation and recruitment domain (CARD) or via the adaptor protein ASC. Caspase-1 then assembles into its active form which obtains the peptidase activity. The metabolic process performed by caspase-1 includes the proteolytic cleavage of pro-IL-1 β at Asp116 into IL-1 β [72] and cleavage of pro-IL-18 into IL-18 to induce IFN- γ secretion and natural killer cell activation [73]. Thus, the inflammasome promotes the maturation of the inflammatory cytokines, interleukin 1 β (IL-1 β) and interleukin 18 (IL-18) [72]. Thus, IL-1R signaling is considered to play a crucial role in inflammasome activation-induced inflammation.

Nucleotide oligomerization domain (NOD)-like receptor family, pyrin domain 3 (NLRP3) containing inflammasome is an intracellular multiprotein complex, which has been verified to participate in A β -induced neuroinflammation [74]. Halle et al. demonstrated that the phagocytosis of fibrillar A β activates NALP3 inflammasomes in mouse microglia. The activation of NALP3 was dependent on lysosomal damage and cathepsin B release, as was observed earlier

in the crystal-induced NLRP3 activation [75, 76]. Then, more evidence was supportive for that A β activate the NLRP3 inflammasome in microglial cells *in vitro* and *in vivo* [77–79]. NLRP3 inflammasome inhibitor treatment in AD mice led to decreased levels of A β deposition and decreased levels of soluble and insoluble A β 42 in the brain [80]. NLRP3 or caspase-1 knockout could significantly suppress amyloidosis and neuropathology, as well as improve cognition-associated parameters in AD mice model [77].

The possible roles of the NLRP3 inflammasome in AD pathogenesis discussed above open a novel investigation of inflammasome signaling pathway for understanding AD. Designing agents for critically controlling the activation of NLRP3 inflammasome at the molecular level might offer considerable promise to tackle neuroinflammation and slow AD progression.

6. IL-1R signaling in neurons

IL-1R is widely distributed in the central nerves system (CNS). Early evidence revealed that IL-1R was detected in high density in the dentate gyrus of the hippocampus, choroid plexus, meninges, and anterior pituitary and is low expressed in the frontoparietal cortex. Both neurons and glial cells were shown to express IL-1R [81]. Later, a pile of data demonstrated that IL-1R could be activated in various cell types in CNS. In cultured human microglia, numerous proinflammatory cytokines such as IL-1, IL-6, and TNF α are produced after IL-1 stimulation. In cultured rat astrocytes, IL-1 could stimulate astrocytes to release nerve growth factor which can mediate neuroprotective effects [82]. In addition, administration of IL-1 in the cerebral ventricle induced COX-2 exclusively in endothelial cells comprising brain blood vessels [83]. As we described in the previous paragraph, IL-1R plays an important role in glial activation-induced neuroinflammation, the participation of IL-1R in neuronal function has not been carefully discussed.

IL-1 β has been reported to increase the expression of APP in neuronal culture [69]. The amyloid precursor protein (APP), via stimulation of amyloidogenic processing, undergoes sequential proteolytic cleavage by β -secretase and γ -secretase to generate A β . Alternatively, a non-amyloidogenic pathway involving α -secretase activation could reduce A β generation, which competitively inhibits activation of the detrimental amyloidogenic pathway. Also, sAPP α is proven to possess neuroprotective and memory-enhancing properties, often being compared to cerebral growth stimulants. Thus, the non-amyloidogenic pathway is supposed to be a suitable therapeutic target for AD.

The identity of α -secretase of APP has been verified to be ADAM10 (a disintegrin and metalloprotease 10) constitutively and ADAM17 regulatively [84]. Different kinds of stimuli have been suggested to increase the secretion of sAPP α under certain conditions via ADAM17, including various cytokine, chemokines, adhesion molecules and growth factors [85]. The two most important ligands for IL-1R, IL-1 α [86] and IL-1 β [87, 88] were proved to enhance ADAM17 activity in neurons. The detail mechanism research concerning to IL-1 signaling and APP proteolysis revealed that the GC-rich APP mRNA 5'UTR-stem loop structure bears an amyloid-specific CAGA sequence, IL-1 responsive element, and an iron responsive element.

IL-1 binding to its responsive element significantly impacts the functioning of APP 5'UTR that affects APP metabolism and thus sAPP α release [89]. Besides, p38/ERK/JNK pathway and PI3K/AKT pathway are believed to participate in IL-1 signaling mediated activity regulation of APP α -secretase ADAM17 [90, 91].

Thus, IL-1R is considered play an important and distinct role in different aspects in the process of AD development. The exact relationship of IL-1R signaling activation between microglial activation-induced neuroinflammation and APP α -shedding in neurons is somehow tricky. The cytokines and growth factors from reactive microglia induced by neurotoxic A β may enhance ADAM17 activity in nearby neurons (paracrine), which provides a possible self-protection against Ab-induced neuronal dystrophy.

7. Conclusion

IL-1R participates in AD-related neuroinflammation by microglial activation and the secretion of various pro-inflammatory cytokines and chemokines. The anti-inflammation treatment has been raised up, including IL-1R antagonist as a potential AD therapeutic approach. However, IL-1R activation in neurons, where exactly APP proteolysis takes place, may enhance the activity of neuroprotective α -secretase. The safety of novel promising therapeutic approaches targeting IL-1R activity regulation has to be evaluated carefully to avoid unexpected side effects.

Acknowledgements

This work was financially supported by National Natural Science Foundation of China (81302781).

Author details

Huanhuan Wang^{1*} and Xizhen Wang²

*Address all correspondence to: huanval@hznu.edu.cn

1 School of Medicine, Hangzhou Normal University, Hangzhou, China

2 Vastec Medical LTD, Hong Kong, China

References

- [1] Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: A Delphi consensus study. *Lancet*. 2005;**366**(9503):2112-2117

- [2] Goate A. Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer's disease. *Journal of Alzheimer's Disease*. 2006;**9**(3 Suppl):341-347
- [3] Sundstrom A, Nilsson LG, Cruts M, Adolfsson R, Van Broeckhoven C, Nyberg L. Increased risk of dementia following mild head injury for carriers but not for non-carriers of the APOE epsilon4 allele. *International Psychogeriatrics*. 2007;**19**(1):159-165
- [4] Savva GM, Stephan BC. Epidemiological studies of the effect of stroke on incident dementia: A systematic review. *Stroke*. 2010;**41**(1):e41-e46
- [5] Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. *PLoS One*. 2009;**4**(1):e4144
- [6] Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. *The Lancet Neurology*. 2005;**4**(8):487-499
- [7] Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. *The American Journal of Geriatric Psychiatry*. 2008;**16**(5):343-354
- [8] McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *The Cochrane Database of Systematic Reviews*. 2016;**1**:CD003160
- [9] Selkoe DJ, Schenk D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. *Annual Review of Pharmacology and Toxicology*. 2003;**43**:545-584
- [10] Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease *Lancet*. 2011;**377**(9770):1019-1031
- [11] Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. *Lancet*. 2016;**388**(10043):505-517
- [12] Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). *Neuron*. 1994;**13**(1):45-53
- [13] Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature*. 1999;**399**(6738 Suppl):A23-A31
- [14] Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. *Annual Review of Biochemistry*. 1997;**66**:385-407
- [15] Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. *Physiological Reviews*. 2001;**81**(2):741-766
- [16] Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? *Current Alzheimer Research*. 2006;**3**(1):71-73
- [17] Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere

- AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*. 1999;**286**(5440):735-741
- [18] Sisodia SS, St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: Where do the presenilins fit in? *Nature Reviews Neuroscience*. 2002;**3**(4):281-290
- [19] Fraser PE, Darabie AA, McLaurin JA. Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides: Implications for drug development. *The Journal of Biological Chemistry*. 2001;**276**(9):6412-6419
- [20] Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nature Medicine*. 2000;**6**(8):916-919
- [21] Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. *The Cochrane Database of Systematic Reviews*. 2006;**1**:CD001190
- [22] Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. *The Cochrane Database of Systematic Reviews*. 2006;**1**:CD001747
- [23] Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. *The Cochrane Database of Systematic Reviews*. 2015;**9**:CD001191
- [24] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*. 2002;**297**(5580):353-356
- [25] McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. *Neurology*. 1996;**47**(2):425-432
- [26] Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? *The New England Journal of Medicine*. 2001;**345**(21):1567-1568
- [27] Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. *Neurology*. 2008;**70**(19):1672-1677
- [28] Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. *Proceedings of the National Academy of Sciences of United States of America*. 2000;**97**(4):1456-1460
- [29] Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. *American Journal of Pathology*. 2001;**158**(4):1345-1354
- [30] Wirz KT, Bossers K, Stargardt A, Kamphuis W, Swaab DF, Hol EM, Verhaagen J. Cortical beta amyloid protein triggers an immune response, but no synaptic changes

- in the APPswe/PS1dE9 Alzheimer's disease mouse model. *Neurobiology of Aging*. 2013;**34**(5):1328-1342
- [31] Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. *Neurobiology of Aging*. 2006;**27**(12):1763-1768
- [32] Forlenza OV, Diniz BS, Talib LL, Mendonca VA, Ojopi EB, Gattaz WF, Teixeira AL. Increased serum IL-1 β level in Alzheimer's disease and mild cognitive impairment. *Dementia and Geriatric Cognitive Disorders*. 2009;**28**(6):507-512
- [33] Giuliani F, Vernay A, Leuba G, Schenk F. Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF- α metabolism. *Brain Research Bulletin*. 2009;**80**(4-5):302-308
- [34] McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. *Neurobiology of Disease*. 2009;**34**(1):163-177
- [35] Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. The significance of neuroinflammation in understanding Alzheimer's disease. *Journal of Neural Transmission (Vienna)*. 2006;**113**(11):1685-1695
- [36] Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. *Journal of Neuroimmunology*. 2007;**184**(1-2):69-91
- [37] Das S, Basu A. Inflammation: A new candidate in modulating adult neurogenesis. *Journal of Neuroscience Research*. 2008;**86**(6):1199-1208
- [38] Bolos M, Perea JR, Avila J. Alzheimer's disease as an inflammatory disease. *Biomolecular Concepts*. 2017;**8**(1):37-43.
- [39] Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. In-vivo measurement of activated microglia in dementia. *Lancet*. 2001;**358**(9280):461-467
- [40] Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. *Biological Psychiatry*. 2010;**68**(10):930-941
- [41] Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strommeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. *Neurobiology of Aging*. 2000;**21**(3):383-421

- [42] Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. *Brain Research. Brain Research Reviews*. 2005;**48**(1):16-42
- [43] Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. *Cell*. 2010;**140**(6):918-934
- [44] Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. *Cellular Physiology and Biochemistry*. 2007;**20**(6):947-956
- [45] Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. *Journal of Neurochemistry*. 2008;**104**(2):524-533
- [46] Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. *The FASEB Journal*. 2004;**18**(1):203-205
- [47] Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. *Journal of Neuroscience*. 2004;**24**(44):9838-9846
- [48] Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. *Nature Immunology*. 2010;**11**(2):155-161
- [49] Hines DJ, Choi HB, Hines RM, Phillips AG, MacVicar BA. Prevention of LPS-induced microglia activation, cytokine production and sickness behavior with TLR4 receptor interfering peptides. *PLoS One*. 2013;**8**(3):e60388
- [50] Go M, Kou J, Lim JE, Yang J, Fukuchi KI. Microglial response to LPS increases in wild-type mice during aging but diminishes in an Alzheimer's mouse model: Implication of TLR4 signaling in disease progression. *Biochemical and Biophysical Research Communications*. 2016;**479**(2):331-337
- [51] Manocha GD, Floden AM, Rausch K, Kulas JA, McGregor BA, Rojanathammanee L, Puig KR, Puig KL, Karki S, Nichols MR, Darland DC, Porter JE, Combs CK. APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*. 2016;**36**(32):8471-8486
- [52] Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. *Journal of Neuroinflammation*. 2005;**2**:22

- [53] Cui YH, Le Y, Zhang X, Gong W, Abe K, Sun R, Van Damme J, Proost P, Wang JM. Up-regulation of FPR2, a chemotactic receptor for amyloid beta 1-42 (A beta 42), in murine microglial cells by TNF alpha. *Neurobiology of Disease*. 2002;**10**(3):366-377
- [54] Neher JJ, Neniskyte U, Brown GC. Primary phagocytosis of neurons by inflamed microglia: potential roles in neurodegeneration. *Frontiers in Pharmacology*. 2012;**3**:27
- [55] Boraschi D, Tagliabue A. The interleukin-1 receptor family. *Vitamins and Hormones*. 2006;**74**:229-254
- [56] O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. *Immunological Reviews*. 2008;**226**:10-18
- [57] Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. *Annual Review of Immunology*. 2011;**29**:447-491
- [58] Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. *Biochimica et Biophysica Acta*. 2002;**1592**(3):265-280
- [59] Li Q, Verma IM. NF-kappaB regulation in the immune system. *Nature Reviews Immunology*. 2002;**2**(10):725-734
- [60] Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family—Balance between agonists and antagonists in inflammatory diseases. *Cytokine*. 2015;**76**(1):25-37
- [61] Kwak A, Lee Y, Kim H, Kim S. Intracellular interleukin (IL)-1 family cytokine processing enzyme. *Archives of Pharmacal Research*. 2016;**39**(11):1556-1564
- [62] Benzing WC, Wujek JR, Ward EK, Shaffer D, Ashe KH, Younkin SG, Brunden KR. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. *Neurobiology of Aging*. 1999;**20**(6):581-589
- [63] Holmes C, El-Okli M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. *Journal of Neurology, Neurosurgery, and Psychiatry*. 2003;**74**(6):788-789
- [64] Williamson LL, Sholar PW, Mistry RS, Smith SH, Bilbo SD. Microglia and memory: Modulation by early-life infection. *Journal of Neuroscience*. 2011;**31**(43):15511-15521
- [65] Barrientos RM, Hein AM, Frank MG, Watkins LR, Maier SF. Intracisternal interleukin-1 receptor antagonist prevents postoperative cognitive decline and neuroinflammatory response in aged rats. *Journal of Neuroscience*. 2012;**32**(42):14641-14648
- [66] Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron*. 2007;**53**(3):337-351

- [67] Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. *Journal of Neuroscience*. 2003;**23**(5):1605-1611
- [68] Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. *Journal of Neuroscience*. 2005;**25**(39):8843-8853
- [69] Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. *The Journal of Immunology*. 2011;**187**(12):6539-6549
- [70] Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, Booth SJ, White CS, Baldwin AG, Freeman S, Wong R, Latta C, Yu S, Jackson J, Fischer N, Koziel V, Pillot T, Bagnall J, Allan SM, Paszek P, Galea J, Harte MK, Eder C, Lawrence CB, Brough D. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. *Nature Communications*. 2016;**7**:12504
- [71] Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. *Infection and Immunity*. 2005;**73**(4):1907-1916
- [72] Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Molecular Cell*. 2002;**10**(2):417-426
- [73] Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, Harding MW, Livingston DJ, Su MS. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. *Science*. 1997;**275**(5297):206-209
- [74] Wang K, Yao Y, Zhu X, Zhang K, Zhou F, Zhu L. Amyloid beta induces NLRP3 inflammasome activation in retinal pigment epithelial cells via NADPH oxidase- and mitochondria-dependent ROS production. *Journal of Biochemical and Molecular Toxicology*. 2016; Epub.
- [75] Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. *Nature Immunology*. 2008;**9**(8):857-865
- [76] Gustin A, Kirchmeyer M, Koncina E, Felten P, Losciuto S, Heurtaux T, Tardivel A, Heuschling P, Dostert C. NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. *PLoS One*. 2015;**10**(6):e0130624
- [77] Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT. NLRP3 is

- activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature*. 2013;**493**(7434):674-678
- [78] Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, Moore KJ. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. *Nature Immunology*. 2013;**14**(8):812-820
- [79] Gold M, El Khoury J. beta-Amyloid, microglia, and the inflammasome in Alzheimer's disease. *Seminars in Immunopathology*. 2015;**37**(6):607-611
- [80] Yin J, Zhao F, Chojnacki JE, Fulp J, Klein WL, Zhang S, Zhu X. NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's disease. *Molecular Neurobiology*. 2017; Epub.
- [81] Ban EM. Interleukin-1 receptors in the brain: Characterization by quantitative in situ autoradiography. *ImmunoMethods*. 1994;**5**(1):31-40
- [82] Gadiant RA, Cron KC, Otten U. Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. *Neuroscience Letters*. 1990;**117**(3):335-340
- [83] Cao C, Matsumura K, Shirakawa N, Maeda M, Jikihara I, Kobayashi S, Watanabe Y. Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. *European Journal of Neuroscience*. 2001;**13**(9):1781-1790
- [84] Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *The EMBO Journal*. 2010;**29**(17):3020-3032
- [85] Qian M, Shen X, Wang H. The distinct role of ADAM17 in APP proteolysis and microglial activation related to Alzheimer's disease. *Cellular and Molecular Neurobiology*. 2016;**36**(4):471-482
- [86] Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT. Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. *Journal of Neuroscience Research*. 2006;**84**(1):106-118
- [87] Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, Murayama S, Endo T, Sakaguchi G, Kato A, Kitazume S, Hashimoto Y. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. *Journal of Neurochemistry*. 2008;**104**(5):1387-1393
- [88] Kong Q, Peterson TS, Baker O, Stanley E, Camden J, Seye CI, Erb L, Simonyi A, Wood WG, Sun GY, Weisman GA. Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. *Journal of Neurochemistry*. 2009;**109**(5):1300-1310

- [89] Wang YQ, Qu DH, Wang K. Therapeutic approaches to Alzheimer's disease through stimulating of non-amyloidogenic processing of amyloid precursor protein. *European Review for Medical and Pharmacological Sciences*. 2016;**20**(11):2389-2403
- [90] Mudher A, Chapman S, Richardson J, Asuni A, Gibb G, Pollard C, Killick R, Iqbal T, Raymond L, Varndell I, Sheppard P, Makoff A, Gower E, Soden PE, Lewis P, Murphy M, Golde TE, Rupniak HT, Anderton BH, Lovestone S. Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. *Journal of Neuroscience*. 2001;**21**(14):4987-4995
- [91] Ma G, Chen S, Wang X, Ba M, Yang H, Lu G. Short-term interleukin-1(beta) increases the release of secreted APP(alpha) via MEK1/2-dependent and JNK-dependent alpha-secretase cleavage in neuroglioma U251 cells. *Journal of Neuroscience Research*. 2005;**80**(5):683-692